Article
C-RAF mutations confer resistance to RAF inhibitors.
Cancer research - 1 Aug 2013
Antony Rajee, Emery Caroline M, Sawyer Allison M, Garraway Levi A
Abstract excerpt
Melanomas that contain B-RAF(V600E) mutations respond transiently to RAF and MEK inhibitors; however, resistance to these agents remains a formidable challenge. Although B- or C-RAF dysregulation represents prominent resistance mechanisms, resistance-associated point mutations in RAF oncoproteins are surprisingly rare. To gain insights herein, we conducted random mutagenesis screens to identify B- or C-RAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.